At the time of writing, Cymabay Therapeutics Inc [CBAY] stock is trading at $32.47, up 0.09%. An important factor to consider is whether the stock is rising or falling in short-term value. The CBAY shares have gain 0.53% over the last week, with a monthly amount glided 1.09%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 4, March 2024, CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis. In a post published today on Yahoo Finance, MAA Validation Follows Recent Applications for Seladelpar to the U.K. MHRA and U.S. FDA.
From an analyst’s perspective:
Cymabay Therapeutics Inc [NASDAQ: CBAY] stock has seen the most recent analyst activity on February 13, 2024, when Raymond James downgraded its rating to a Mkt Perform. Previously, UBS started tracking the stock with Buy rating on August 14, 2023, and set its price target to $18. On August 11, 2023, Guggenheim initiated with a Buy rating and assigned a price target of $20 on the stock. William Blair started tracking the stock assigning a Outperform rating. BTIG Research initiated its recommendation with a Buy and recommended $15 as its price target on March 09, 2023. In a note dated August 04, 2020, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $9 to $13.
For the past year, the stock price of Cymabay Therapeutics Inc fluctuated between $7.26 and $32.47. Cymabay Therapeutics Inc [NASDAQ: CBAY] shares were valued at $32.47 at the most recent close of the market.
Analyzing the CBAY fundamentals
Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -3.27%, Pretax Profit Margin comes in at -3.39%, and Net Profit Margin reading is -3.59%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.54 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.37.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 32.44 points at the first support level, and at 32.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 32.49, and for the 2nd resistance point, it is at 32.50.
Cymabay Therapeutics Inc [CBAY] reported earnings per share of -$0.35 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.31/share, meaning a difference of -$0.04 and a surprise factor of -12.90%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.32 per share as compared to estimates of -$0.29 per share, a difference of -$0.03 representing a surprise of -10.30%.
Ratios To Look Out For
It is important to note that Cymabay Therapeutics Inc [NASDAQ:CBAY] has a current ratio of 10.96. On the other hand, the Quick Ratio is 10.96, and the Cash Ratio is 5.61. Considering the valuation of this stock, the price to sales ratio is 119.95, the price to book ratio is 12.65.
Transactions by insiders
Recent insider trading involved Dorling Janet, Director, that happened on Feb 12 ’24 when 6000.0 shares were sold. President of R&D, McWherter Charles completed a deal on Jan 19 ’24 to sell 18403.0 shares. Meanwhile, Vice President, Finance Menold Daniel sold 10000.0 shares on Jan 16 ’24.
